Objective: To compare adjunctive long-acting injectable risperidone plus treatment as usual (RLAI+TAU) versus TAU alone for relapse, rehospitalization, and urgent care events in patients with bipolar disorder in routine care settings.
B ipolar disorder is a severe and recurring mood disorder that is associated with profound morbidity, mortality, and economic burden. 1Y3 Owing to its recurring nature, long-term maintenance pharmacotherapy is often needed to prevent illness relapses in patients with bipolar disorder. 4, 5 Several pharmacotherapies, alone or in combination, may be effective for preventing mainly manic/mixed episode relapses during maintenance treatment. 6 However, even with maintenance treatment, relapse rates in persons with bipolar disorder remain high. 7 One important mechanism for acute illness relapse in bipolar disorder is poor adherence to treatment. 8Y10 Indeed, premature discontinuation of pharmacotherapy is the leading cause of bipolar relapse and recurrence 8, 11 and is associated with higher psychiatric hospitalization risk, hospital bed-day consumption, and treatment costs in bipolar patients. 12 A potential pragmatic solution to the problem of poor treatment adherence in bipolar disorder is the use of long-acting injectable medication during maintenance-phase therapy. The use of long-acting typical neuroleptics for this indication is limited by several factors, including the risk of depressive symptom exacerbation 13Y15 and development of tardive dyskinesia. 16, 17 Longacting injectable risperidone (RLAI), an atypical antipsychotic drug, is approved in the United States for the maintenance treatment of bipolar I disorder. 18 Data from 3 randomized relapse prevention trials in patients with predominantly bipolar I disorder indicate that RLAI is effective for preventing acute mania relapses during maintenance-phase treatment, 19Y21 without worsening depressive symptoms. 19 There are some limitations to the generalizability of these study findings to patients who receive care in routine treatment settings. None of these studies were conducted exclusively in community-based settings, and all excluded patients with substance use disorders. Only one study enrolled patients with frequent illness relapses 20 or those with bipolar II disorder. 21 The objective of this study was to compare the effects of adjunctive RLAI (added to treatment as usual [TAU] ) with TAU alone on rates of relapse, psychiatric hospitalization, and urgent care referral in adults with rapid cycling bipolar disorder in a community practice setting over 12 months.
Edition, Text Revision criteria for bipolar I or II disorder were recruited from a single large community-based treatment center. Clinical diagnoses were confirmed using the Mini International Neuropsychiatric Interview. 22 The current mood state was not a determinant of eligibility. Eligible subjects had a Young Mania Rating Scale (YMRS) 23 or Hamilton Depression (17-item) Rating Scale 24 scores of 8 or higher at screening and a history of 4 or more symptomatic relapses in the year before study participation, with at least one symptomatic relapse in the previous 6 months. Eligible patients were physically healthy, capable of providing informed consent, and able to complete self-administered questionnaires.
Subjects were excluded if they had active psychotic symptoms (hallucinations or delusions) at the time of study entry, history of nonresponse to RLAI, high suicide risk (rating of 4 on the suicide item [item 3] of the Hamilton Depression Rating Scale, 24 or determination by the investigator of significant suicide risk), a psychiatric hospitalization between screening and baseline visits, or medical contraindication or hypersensitivity to oral risperidone or RLAI. Patients were not excluded on the basis of past risperidone treatment, or history of risperidone nonresponse or intolerance. Pregnant or nursing patients were ineligible.
Psychiatric comorbidity and recent substance abuse were not considered exclusionary as long as bipolar disorder was the principal condition under treatment and the treating physician and principal investigator deemed RLAI treatment was safe.
Design and Procedures
Eligible subjects were randomized 1:1 (via a computergenerated randomization list maintained off-site by the study coordinator) to RLAI+TAU or TAU alone. Individuals who were assigned to RLAI+TAU were initiated on oral risperidone at a minimum dosage of 0.5 mg daily. Long-acting injectable risperidone was initiated at a dosage of either 12.5 mg or 25 mg intramuscular every 2 weeks. For those started on 12.5 mg, RLAI was titrated to 25 mg every 2 weeks as tolerated. Further dose adjustments (to 37.5 or 50 mg every 2 weeks) were made at the study physicians'discretion, or if: (1) the YMRS score was greater than 12; or (2) there was clinical evidence of an impending relapse. Treatment as usual consisted of oral antipsychotics (other than risperidone) and/or mood stabilizers, with or without concomitant antidepressants, at the discretion of the study physicians. Other physicians were instructed to optimize TAU medications as vigorously as required to effectively treat symptoms while maintaining acceptable tolerability. Compliance was monitored by patient self-report. Anticholinergic medications and benzodiazepines were allowed on a temporary basis to manage adverse effects as clinically indicated.
Clinical assessments occurred at baseline and every 2 weeks during the study period. Follow-up was continued for 52 weeks, even if a relapse or psychiatric hospitalization occurred. Gaps in follow-up were allowed during the 52-week study period; however, missed study visits did not count toward total person-time. Thus, if a patient missed one study visit but was otherwise continuously followed for the full 52 weeks, s/he contributed only 50 weeks (0.96 person-years) of follow-up.
This study was approved by the institutional review board of Vanderbilt University Medical Center and was conducted in accordance with the ethical principles originating from the Declaration of Helsinki and good clinical practices. All participants provided written informed consent.
Efficacy Measures and End Points
Clinical outcome was assessed every 2 weeks using the Longitudinal Interval Follow-up Evaluation. 25 Psychopathology and quality of life were measured at baseline and monthly thereafter using the Young Mania Rating Scale (YMRS), 23 the Montgomery-Asberg Depression Rating Scale (MADRS), 26 the Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR), 27 and the Quality of Life, Enjoyment, and Satisfaction Questionnaire. 28 The YMRS and the MADRS were administered by trained and experienced research staff whose interrater reliability was assessed on a quarterly basis as approximately 95%.
The main end points of interest were the number and duration relapse events per person-year of follow-up. Relapse events were defined as occurrence of any of the following at any study visit: (1) a YMRS score higher than 14 or a MADRS score higher than 15; (2) 20% or greater increase in the YMRS or MADRS scores from the previous study visit for patients with a MADRS score of 10 or higher or a YMRS score of 8 or higher at the current study visit; (3) urgent care visit/referral (psychiatric hospitalization; emergency department visit; or referral for respite care, partial hospitalization, or intensive outpatient treatment) due to worsening mood symptoms; (4) a Clinical Global ImpressionV Severity of Illness score lf 4 or higher; (5) syndromal relapse (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision criteria for manic, hypomanic, major depressive, or mixed episode met); (6) withdrawal from the study due to inefficacy; and (7) necessary clinical medication adjustments (NCAs). Relapse event duration was based on the number of weeks that any relapse criteria were met. However, discrete events (medication changes, ED visits) were treated as count data only. Necessary clinical medication adjustments were defined as change in medication treatment intended to prevent worsening of clinical symptoms, and included addition of a new mood stabilizer, nonrisperidone antipsychotic, or antidepressant; substitution of an existing bipolar medication with a new drug; and/or a 20% or greater change in dose of any current medication (excluding routine increases in dose due to titration).
Thus, the main study end point was relapse for any of the earlier-specified reasons (any-cause relapse event). Exploratory end points included the occurrence of each of the 7 individual relapse event types, and scores on the aforementioned psychopathology and quality of life measures.
Safety and Tolerability Measures
Treatment-emergent adverse events (TEAEs) were ascertained by spontaneous report and changes in laboratory values (fasting glucose, lipids, serum chemistries, and prolactin concentration). Anthropometric measures were not formally assessed. Neuromuscular adverse effects were assessed using the Abnormal Involuntary Movement Scale (AIMS), 29 the Barnes Akathisia Scale (BARS), 30 and the Simpson-Angus Rating Scale (SAS). 31 
Data Analytic Approach
The modified intent-to-treat (ITT) sample included all persons who were randomized, received study medication, and had at least 1 follow-up visit. All subjects were analyzed according to their allocated treatment group. Because of the variable follow-up time for individual subjects, both the number of relapse events and duration of relapses during the follow-up were calculated as the number (or duration [weeks]) of events per person per year of follow-up.
Categorical baseline characteristics were compared between conditions with W 2 tests. Continuous and ordinal baseline data were analyzed via the Student t test and the Wilcoxon rank sum test, respectively. Mean number and duration of relapse events normalized to person-time, as defined earlier, were compared between groups using the Student t test. A mixed-model repeated-measures approach was used to model the effects of treatment (RLAI+TAU vs TAU alone) on continuous psychopathology and safety measures at each time point. To account for baseline differences in these measures, the mixed-model repeatedmeasures analyses were adjusted for baseline-dependent measure values.
All tests were conducted with a significance level of P = 0.05 (2-sided), with no adjustments for multiplicity, using SAS statistical software (SAS Institute, Inc, 1994).
RESULTS
Fifty of 60 screened patients were randomized to receive RLAI+TAU (n = 25) or TAU alone (n = 25; Fig. 1 ). Of these, 20 patients in the RLAI+TAU group and 25 in the TAU alone group received at least 1 dose of study drug and had at least 1 postbaseline follow-up assessment. Thus, 45 subjects were included in the analysis. The mean RLAI dose at the study end point was 27.0 T 10.4 mg every 2 weeks. None of the RLAItreated patients required titration to 50 mg/d. Very few patients required low-dose benzodiazepines (n = 1 in each group) or anticholinergic medications (RLAI+TAU, n = 1; TAU only, n = 3). For most of the RLAI+TAU patients, RLAI was the only antipsychotic drug taken (Appendices 2 and 3); however, some patients continued their prestudy oral antipsychotics (n = 4 at 6 months; n = 2 at 12 months) or started oral antipsychotics after randomization (n = 2 at 6 months).
The mean duration of follow-up in the total sample was 43.1 T 15.2 weeks, with no significant differences in the follow-up time between treatment groups. Four patients assigned to the RLAI+TAU group and 6 patients assigned to TAU alone dropped out before the end of month 12 and did not return for subsequent study visits (P = NS). Nearly all withdrawals in both groups were due to loss of follow-up (RLAI+TAU, n = 2; TAU only, n = 6). One subject in the RLAI+TAU group moved out of the area before completing the study, and one subject did not tolerate RLAI.
There were no significant between-group differences in demographic/clinical characteristics or baseline psychopathology measures, as shown in Table 1 . The sample consisted predominantly of females, whites, and patients with bipolar I disorder, although approximately one fourth of the participants had a diagnosis of bipolar II disorder. More than three quarters of the sample had a comorbid anxiety disorder, substance use disorder, or both. Before study entry, most patients were receiving an approved mood stabilizer, typically in combination with an oral atypical antipsychotic drug and/or antidepressant ( Table 1) . Doses of individual oral psychotropic medications used in both treatment groups were considered to be generally appropriate (see Appendices).
The RLAI+TAU group was associated with fewer mean any-cause relapse events and shorter mean time spent in an anycause relapse event, compared with TAU alone ( Table 2) . However, these differences were not statistically significant. When individual relapse events were considered separately, significantly fewer acute depressive episodes, urgent care events, and NCAs occurred in the RLAI+TAU group than in the TAU group. Altogether, 14 urgent care referrals occurred among 7 persons (RLAI+TAU, n = 1 [5.0%] vs TAU alone, n = 6 [24.0%]; Fisher exact test, P = NS). Thirteen (92.3%) of the 14 urgent care events occurred in the TAU alone group. Nearly all subjects randomized to TAU alone (n = 24 [96.0%]) and most of the subjects randomized to RLAI+TAU (n = 12 [60.0%]) required an NCA (Fisher exact test, P = 0.006). No significant between-group differences in the number or duration of other types of relapse events were observed, including no significant differences in the duration of depressive relapses. A significant time effect was observed for the QIDS-SR, indicating that patient-reported depressive symptoms improved in the whole sample (Table 3 ). However, there was no significant group Â time interaction effect for any psychopathology measure, indicating that changes in these scores did not differ FIGURE 1. Disposition of subjects through the study. *Of the 25 subjects randomized to RLAI + TAU, 4 did not receive study drug, whereas one received study drug but did not have any follow-up visits after their baseline visit. Data from the 20 remaining patients were used in the data analysis. † Four patients randomized to RLAI + TAU and 6 patients randomized to TAU alone dropped out before the final study visit (at the end of month 12). All of these patients had at least 1 study visit after their baseline visit. Thus, all of these patients (20 in the RLAI+TAU group and 25 in the TAU-alone group) were eligible to be included in the data analysis. significantly by treatment group over time (Table 3) . No significant changes in the MADRS or QIDS-SR scores over time were observed in either group. There were also no significant differences in baseline-to-end point change in the Clinical Global ImpressionVSeverity of Illness or the Quality of Life, Enjoyment, and Satisfaction Questionnaire subscale scores (data not shown).
The most common TEAEs in the RLAI+TAU group were sedation (n = 3) and subjective weight gain (n = 2). Two patients experienced potential prolactin-related adverse events (PPRAEs, galactorrhea, n = 1; menstrual changes, n = 1). The most common TEAEs in the TAU only group were sedation (n = 4), som-nolence (n = 4), and subjective weight gain (n = 3). None of the patients in the TAU only group reported potential prolactin-related adverse events. Adverse effects related to basal ganglia dysfunction (including extrapyramidal effects) were reported by 4 subjects in the RLAI+TAU group and 6 subjects in the TAU-alone group.
There were no significant group or group Â time interaction effects for AIMS or BARS scores (Table 4 ). Significant time and group Â time interaction effects were observed for SAS scores. There were no significant changes in the SAS scores from baseline in the RLAI+TAU group; however, in the TAU-alone group, there was a significant increase (worsening) in the SAS scores at 9 months. Increases in the SAS scores of 5 points or greater were observed in 5 TAU patients who were taking haloperidol (n = 1), quetiapine (n = 3), or ziprasidone (n = 1). There were no significant differences in AIMS, BARS, or SAS scores baseline and 1, 3, 6, or 12 months among RLAI+TAU patients who received concomitant oral antipsychotics, RLAI+TAU patients who did not receive oral antipsychotics, and those who received TAU only (data not shown).
Baseline glucose values were available for only 56.5% of RLAI+TAU-treated patients and 50.0% of those who received TAU alone. Fasting lipid data were available for only 44.8% and 48.5% of RLAI+TAU-and TAU-onlyYtreated patients, respectively. For those with available data, there were no significant between-group differences in the mean fasting glucose or lipid values at baseline or at study end point (data not shown). For those with complete follow-up data, there was no significant baseline-to-end point change in glucose or lipid measures in either group (data not shown).
No suicide attempts occurred for any of the study subjects. There were no significant between-groups differences in mean or median suicide item scores for either the QIDS-SR (item 12, 0Y3 scale) or MADRS (item 10, 0Y6 scale) at baseline. There were also no significant between-groups differences in the proportion of patients achieving a score of 2 or higher on either 
DISCUSSION
This preliminary study is a first attempt at extending results of a large phase 3-type randomized, double-blind, placebocontrolled RLAI bipolar maintenance studies to a representative sample of rapid cycling, community-treated patients with bipolar I or II disorder over 52 weeks of follow-up. Neither the rate nor the duration of any-cause relapse or episodic mood relapse, the primary study end points, differed significantly according to treatment group. However, a significantly lower number of urgent care events and NCAs per year of follow-up were observed with RLAI+TAU. There were fewer depressive relapses per person per year of follow-up in the RLAI+TAU group; however, no significant between-groups differences in the duration of depressive relapses or in psychopathology scores were observed. Betweengroup differences were significant only for secondary outcome measures; however, if supported by further research, these findings could indicate that bipolar patients who require repeated advanced care options such as hospitalizations, emergency department visits, or respite care might preferentially benefit from adjunctive RLAI.
Very few maintenance-phase data are available regarding the effectiveness of antipsychotic drugs in patients with rapid cycling. 6 Small open-label studies and subgroup analyses of short-term randomized controlled trials suggest that olanzapine, †Refers to comorbid Axis I diagnoses according to the MINI for nonYsubstance-related diagnoses, and both the MINI and clinical records for substance use disorder diagnoses. Note that counts will not add up to 100% as categories are not mutually exclusive. quetiapine, and aripiprazole may be more effective for treating manic/mixed symptoms than depressive symptoms in rapid cycling bipolar patients. 32 However, long-term follow-up studies focused on the maintenance effects of these drugs in rapid cycling bipolar patients are sparse. Prior randomized bipolar maintenance studies have documented significantly longer time to recurrence/relapse and lower episodic mood recurrence/relapse rates in patients treated with RLAI. The first of these, conducted by Macfadden et al, 20 was a 52-week randomized double-blind comparison of RLAI+TAU continuation treatment (vs TAU+ placebo) in 124 frequently relapsing patients who had previously remitted during a 16-week open-label lead-in phase. The second study, conducted by Quiroz et al, 19 was a large, 24-month randomized, placebo-controlled, recurrence prevention study in 303 subjects who had previously achieved a stable positive treatment response during a 6-month stabilization phase. In both studies, relapse events were broadly defined and included many of the same elements that were incorporated into our relapse definition. Generalizability of these results to community practice is limited by enrichment of the randomized double-blind phases of each study with patients who had already responded favorably to RLAI, and exclusion of subjects with bipolar II disorder and concomitant substance use disorders. Only the Macfadden et al 20 study targeted frequently relapsing patients.
The only randomized study that did not include a prerandomization lead-in phase and enrolled patients with bipolar II disorder was a 24-week open trial in which 23 subjects were switched to RLAI monotherapy and 26 continued their prestudy oral medication. 21 No significant between-groups differences in manic or depressive symptoms were observed between treatment arms; however, this study focused only on symptom-based outcomes (not relapse events) and excluded patients with substance use disorders.
Although we were unable to replicate previous findings of a statistically significant advantage for RLAI related to anycause relapse or episodic mood relapse, we report novel results for RLAI in a high-risk community-treated population of patients with bipolar I and II disorders. Our selection criteria targeted frequently relapsing patients using criteria similar to that of Macfadden et al. 20 However, unlike previous randomized studies, most of our sample had comorbid anxiety disorders, substance use disorders, or both at rates consistent with other communitybased bipolar samples. 33Y36 Conducting intervention studies in such populations is important, given the well-known challenges imposed by high rates of anxiety and substance-related comorbidity. 33 ,37Y41 Thus, we were able to extend prior findings from more selective patient populations to one that is more representative of community-based practice. Moreover, unlike previous studies that used time to event-analytic designs that censored follow-up after the first postrandomization relapse event, the patients in our study were continuously followed after relapse events occurred. This approach allowed us to collect data on multiple relapse events, an important design consideration given the high relapse rates encountered in routine practice. In addition, we were able to estimate the total person-time spent in a relapse event during a fixed (up to 52 weeks) period of follow-up, which served as a proxy measure of illness burden than could be compared between treatment groups.
Our finding of a statistically significant advantage of adjunctive RLAI for urgent care events and NCAs is also novel. Although urgent care events and NCAs were secondary end points, they are important therapeutic measures that are pertinent to ''real world'' clinical management. Our definition of urgent care event included a wide spectrum of services available in many community mental health systems. Because our urgent care definition also required documentation of worsening mood (2) Q20% increase in YMRS or MADRS scores from the previous study visit for patients with current MADRS Q10 or YMRS Q8; (3) urgent care visit/referral (psychiatric hospitalization, emergency department visit, or referral for respite care or intensive outpatient treatment) due to worsening mood symptoms; (4) CGI-S score Q4; (5) syndromal relapse (DSM-IV-TR criteria for manic, hypomanic, major depressive or mixed episode met); (6) withdrawal from the study due to inefficacy; and/or (7) necessary medication adjustments.
†Defined as psychiatric hospitalization, emergency department visit, or referral for respite care or intensive outpatient treatment due to worsening mood symptoms.
‡Defined as change in medication treatment intended to prevent worsening of clinical symptoms (any of the following: [1] addition of a new mood stabilizer, antipsychotic or antidepressant; [2] substitution of an existing bipolar medication with a new drug; and/or [3] a Q20% change in dose of any current medication). symptoms, this specific end point served as a pragmatic indicator of significant clinical worsening. Medication adjustment to prevent symptom worsening may be expected to occur frequently in community practice, particularly in highly relapse-prone patients. In our study, only medication changes or adjustments intended to prevent worsening of symptoms were defined as NCAs; thus, NCAs also served as a reasonable effectiveness indicator. The degree to which potential differences in medication adherence may have contributed to these differences is uncertain, as oral medication adherence was monitored by patient self-report.
In our study, oral antipsychotics were not restricted to the TAU-alone group. A small number of RLAI+TAU patients received oral antipsychotics. Most of the oral antipsychotic use in the RLAI+TAU group represented continuation of prestudy medication. Whereas there was no evidence of increased extrapyramidal side-effects burden associated with such treatment in our study, others have documented greater adverse effect burden with antipsychotic combination therapy in bipolar patients. 42 Moreover, there is no evidence supporting the use of antipsychotic combinations in bipolar disorder treatment.
Our results are preliminary and should be interpreted with additional limitations in mind. First, given the small sample size of our study, we cannot exclude the possibility of type 2 error for any-cause and episodic mood relapse. Second, because physicians were allowed to adjust the doses of oral medications to optimize their effectiveness and tolerability, the use of TAU in both arms may have obscured between-group differences in relapse occurrence and symptom ratings. Our study was intended to provide preliminary effectiveness evidence for adjunctive RLAI under real-world treatment conditions, and any residual bias not addressed by randomization would be toward null findings. Adjustments intended to prevent relapse or clinical worsening were accounted for in the analysis by including an NCA end point. Third, data regarding index episode (the mood episode type present at the beginning of follow-up) was not ascertained. Index episode polarity seems to predict the polarity of mood episode relapses and may influence therapeutic response to specific pharmacotherapies during maintenance treatment. 43Y45 Fourth, the finding of a statistically significant between-group difference in the number of depressive relapses favoring RLAI+TAU must be interpreted cautiously. Because neither oral risperidone nor RLAI has demonstrated value either acutely or prophylactically, respectively, for bipolar depression, 19, 46 the possibility of type 1 error cannot be excluded. Moreover, no significant differences between treatment groups were noted regarding the duration of depressive relapses, or scores on the MADRS or QIDS-SR. Fifth, weight data were not ascertained. Consistent with prior reports, compliance with fasting laboratory assessments was poor. Thus, potential benefits of long-term adjunctive RLAI treatment are difficult to assess in relation to the risk of metabolic adverse effects. Sixth, because costs of treatment were not estimated in this study, additional investigation is needed to determine the cost-outcome profile of RLAI for bipolar maintenance treatment Next, because we desired to investigate the effects of adjunctive RLAI under conditions relevant to community practice, we chose not to conduct a blinded study. Finally, patient acceptance was not a specific study end point. In real-world practice, concerns about convenience, persistence of adverse effects, injection site pain, and other factors may contribute to high discontinuation rates for RLAI and other long-acting injectable medications in patients with bipolar disorder. 47Y49 In conclusion, rates of any-cause relapse with RLAI+TAU were numerically, but not significantly, lower than that of TAU alone in our sample of community-treated adults with rapid cycling bipolar I or II disorder. However, RLAI as an adjunct to TAU may be beneficial for reducing urgent care episodes and NCAs during maintenance treatment. Replication and extension of these results in future large randomized rater-blinded studies are warranted. All values are least-squares mean (SE) unless otherwise specified.
We used a mixed-model repeated-measures approach with time (baseline, and 1-, 3-, 6-, 9-, 12-month visits) as the within-subjects factor and treatment (RLAI+TAU vs TAU alone) as the between-subjects factor. Analyses were adjusted for baseline dependent measure values. Reported P values reflect between-group differences at the corresponding time point. Statistically significant within-group changes at each time point (relative to baseline values) are represented with asterisks: *P G 0.05, **P e 0.01, ***P e 0.001, ****P e 0.0001, †P G 0.08 (trend) for within-group comparison for each time point against the baseline values. 
